Clinical Trials Logo

Filter by:
NCT ID: NCT03316742 Not yet recruiting - Weight Loss Clinical Trials

Pilot Study on Weight Loss in Guinea Bissau

Start date: October 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to test two versions a weight loss program potentially suitable for implementation in Africa. A successful method would have widespread application in low-income countries, with the potential to improve world health.

NCT ID: NCT03302949 Recruiting - Tuberculosis Clinical Trials

Treating Tuberculosis Wasting With a High-protein Supplement

NUTRIATO
Start date: August 1, 2017
Phase: Phase 4
Study type: Interventional

Undernutrition at the time of diagnosis of active tuberculosis is a risk factor for increased mortality, and lack of weight gain during anti-tuberculous treatment has been linked to an increased relapse risk. The purpose of this study is to test the effect of Lacprodan® DI-8090 whey protein concentrate on anthropometric measures, treatment outcome and health-related quality of life, against standard practice during anti-tuberculous treatment on patients with a BMI <20 living in Guinea-Bissau.

NCT ID: NCT03020147 Not yet recruiting - Low Birth Weight Clinical Trials

Low Birth Weight Follow-up

Start date: February 2017
Phase: N/A
Study type: Observational

The Randomized Control Trail included 4,172 low-birth weight children between February 2008 and September 2013 in Bissau. The children who were included in the RCT and who are living in the Bandim Health Project study area will be visited. The study assistants will ask about the health of the child and of both parents. Furthermore, Bacille Calmette-Guerin (BCG) scar status of both child and parents will be checked.

NCT ID: NCT03017209 Recruiting - Cognitive Function Clinical Trials

Locally Prepared Supplement to Support Growth and Brain Health

Start date: January 2017
Phase: N/A
Study type: Interventional

This study is a randomized controlled trial with a main goal to assess the effects of a locally-prepared food for prevention of malnutrition and stunting, in comparison with standard village practices and also a widely available aid food supplement in 8-12 villages in Guinea-Bissau. The supplement intervention will be for 24-30 weeks. The primary outcome will be cognitive tests of executive function. Secondary outcomes will be changes in standard anthropometric benchmarks of growth, hemoglobin and skin carotenoids in young children living in villages in rural Guinea-Bissau. This is a within-village randomization at the level of the family, and all children will receive a dietary intervention.

NCT ID: NCT02953327 Recruiting - Innate Immunity Clinical Trials

Testing if BCG (Bacille Calmette-Guérin) Vaccination Can Induce Innate Immune Training in Adult People Above 50 Years of Age in Guinea-Bissau

Start date: January 2017
Phase: Phase 4
Study type: Interventional

The propose is to test innate immune training in a pilot study of 40 adults >50 years of age people in Guinea-Bissau. The hypothesis is that BCG vaccination will be associated with increased innate immune training measured as increased cytokine release after in vitro Peripheral Blood Mononuclear Cells (PBMC) stimulation with e.g. Mycobacterium Tuberculosis, Staphylococcus Aureus, Candida Albicans and Streptococcus Pneumoniae.

NCT ID: NCT02943681 Recruiting - Child Mortality Clinical Trials

A Second Dose of Measles Vaccine (MV) in the Second Year of Life

Start date: October 2016
Phase: N/A
Study type: Interventional

This study evaluates the non-specific effects on child mortality and morbidity of a second dose of measles in the second year of life. Half of the study participants will receive a second dose of measles vaccine at 18 months of age while the other half will receive a second dose of measles by 4 years of age or at the end of the study.

NCT ID: NCT02662595 Not yet recruiting - Measles Clinical Trials

mHealth to Increase Measles Immunization - a Randomized Controlled Trial in Guinea-Bissau

mimi
Start date: March 2016
Phase: N/A
Study type: Interventional

The question that this project seeks to answer, is whether mobile phones can be used to increase the measles vaccination coverage and timeliness in Guinea-Bissau. The intervention will be evaluated in terms of direct health outcomes and cost/benefit analysis, generating evidence that could help policy makers making informed decisions about implementing mHealth interventions at a national level. The intervention takes the form of a randomized controlled trial in which text messages (SMS) as well as voice calls are scheduled and delivered to mo thers to remind and encourage them to have their children timely vaccinated against measles. In addition, the messages will include relevant information about opening hours and availability of the measles vaccine at the mothers' local health facilities thus improving coordination. The trial will include three different randomization groups with approx. 350 participants in each group. The first group will receive SMS messages, the second group will receive a voice call in addition to the SMS messages, and the third group is a control group that does not receive any intervention. Study participants will be enrolled following birth at one of three health centers in different rural regions of Guinea-Bissau. Before the measles vaccine is scheduled to be given, at 9 months of age, mothers will receive the intervention message depending on their assigned randomization group. When the measles vaccine is administered, the child will be registered as having received the measles vaccination. A follow-up phone interview will be conducted at 12 months of age for all children participating regardless of randomization group and whether or not they received the measles vaccine. All participating children, who at that time still have not received the measles vaccine, will be offered the vaccine at the expense of the project.

NCT ID: NCT02504203 Recruiting - Infant Mortality Clinical Trials

Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial

BCGrural
Start date: November 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether BCG vaccination shortly after birth can reduce early infant mortality in a rural setting.

NCT ID: NCT02447536 Recruiting - Morbidity Clinical Trials

Trial of Two Strains of BCG

BCGSTRAIN
Start date: May 2015
Phase: Phase 4
Study type: Interventional

The investigators aim to conduct a randomised controlled trial comparing two Bacille Calmette-Guérin (BCG) strains currently used in Guinea-Bissau, the Danish and the Russian, in terms of prevention of neonatal and early life morbidity and mortality, immune responses and adverse events related to BCG vaccination. The primary outcome will be hospital admissions within 6 weeks of age.

NCT ID: NCT01989026 Recruiting - Clinical trials for Early Neonatal Mortality

A Randomized Trial of Providing BCG Vaccination Immediately

Start date: October 2013
Phase: Phase 4
Study type: Interventional

Recent studies show that BCG vaccination reduces neonatal mortality by more than 40%. This effect cannot be explained by prevention of tuberculosis, which is very rare among infants. The protective effect of BCG vaccination is seen already within the first week. It seems that BCG provides a non-specific beneficial immune modulation - thereby reducing overall mortality. Mortality is very high among newborns admitted to the neonatal intensive care unit. If BCG has immediate beneficial effects on the immune system, vaccinating children with BCG as early as possible may save lives. The investigators will test this hypothesis in a randomized trial among newborns in Guinea-Bissau, randomizing newborns admitted to the neonatal intensive care unit at the National Hospital 1:1 to BCG immediately or at discharge (usual practice).